首页> 外国专利> DIAGNOSIS AND THERAPY OF DISEASES RELATING TO A DISPROPORTION OF LUTEINIZING HORMONE/CHORIONIC GONADOTROPIN RECEPTOR (LHR; LHCGR) SPLICE VARIANTS

DIAGNOSIS AND THERAPY OF DISEASES RELATING TO A DISPROPORTION OF LUTEINIZING HORMONE/CHORIONIC GONADOTROPIN RECEPTOR (LHR; LHCGR) SPLICE VARIANTS

机译:诊断和治疗与色氨酸激素/ Chorionic促性腺激素受体受体(LHR; LHCGR)配体变体比例不符的疾病

摘要

The present invention relates to a novel exon of the LHR, namely exon 6A, as well as to mutated forms thereof. Particularly, the present invention relates to a nucleotide sequence of exon 6A, to a nucleotide sequence comprising said nucleotide sequence of exon 6A, to a nucleotide sequence comprising a nucleotide sequence of a splice variant of LHR comprising exon 6A1 to variants or fragments of said nucleotide sequences, as well as to a vector comprising said nucleotide sequences. The present invention further relates to a polypeptide comprising an amino acid sequence encoded by exon 6A or encoded by a splice variant of LHR comprising exon 6A, as well as to variants and fragments of said amino acid sequence. Furthermore, the present invention relates to a host cell genetically engineered with a nucleotide sequence of the present invention or comprising the vector of the present invention. Additionally, the present invention relates to a pharmaceutical composition comprising an inhibitor of exon 6A of LHR. Furthermore, provided herein is a method of diagnosing a disease in a patient which is characterized by an increase of the amount of LHR mRNA comprising exon 6A, to a method for treating, ameliorating or preventing such a disease, as well as to a use of the nucleotide sequence, the vector, the polypeptide or the host cell as provided or the inhibitor of exon 6A as defined in the context of the invention for the preparation of a pharmaceutical composition for the treatment, amelioration or prevention of such a disease. The present invention also refers to a method for treating, ameliorating or preventing a disease which is characterized by an increase of the amount of LHR mRNA comprising exon 6A and to a use of the compounds of the invention and an inhibitor of exon 6A for the preparation of a pharmaceutical composition for the treatment, amelioration or prevention of such a disease.
机译:本发明涉及LHR的新外显子,即外显子6A,及其突变形式。特别地,本发明涉及外显子6A的核苷酸序列,涉及包含外显子6A的所述核苷酸序列的核苷酸序列,涉及包含LHR的剪接变体的核苷酸序列的核苷酸序列,所述LHR的剪接变体包含外显子6A1至所述核苷酸的变体或片段。序列,以及包含所述核苷酸序列的载体。本发明进一步涉及包含由外显子6A编码或由包含外显子6A的LHR的剪接变体编码的氨基酸序列的多肽,以及所述氨基酸序列的变体和片段。此外,本发明涉及用本发明的核苷酸序列遗传工程改造或包含本发明的载体的宿主细胞。另外,本发明涉及包含LHR的外显子6A的抑制剂的药物组合物。此外,本文提供了一种诊断患者疾病的方法,其特征在于包含外显子6A的LHR mRNA的量增加,该方法用于治疗,改善或预防该疾病,以及其用途用于制备用于治疗,改善或预防这种疾病的药物组合物的核苷酸序列,提供的载体,多肽或宿主细胞或本发明上下文中定义的外显子6A抑制剂。本发明还涉及治疗,改善或预防特征在于包含外显子6A的LHR mRNA的量增加的疾病的方法,以及本发明的化合物和外显子6A的抑制剂在制备中的用途。用于治疗,改善或预防这种疾病的药物组合物。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号